Hill-Rom Holdings, Inc. (NYSE:HRC) SVP Deborah Rasin sold 4,739 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $103.97, for a total transaction of $492,713.83. Following the transaction, the senior vice president now directly owns 31,001 shares of the company’s stock, valued at approximately $3,223,173.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
NYSE HRC opened at $103.58 on Friday. The stock has a market cap of $6.99 billion, a P/E ratio of 20.39, a PEG ratio of 1.78 and a beta of 0.83. The company’s 50-day simple moving average is $102.55 and its 200 day simple moving average is $103.26. Hill-Rom Holdings, Inc. has a twelve month low of $81.85 and a twelve month high of $111.63. The company has a quick ratio of 1.10, a current ratio of 1.31 and a debt-to-equity ratio of 1.13.
Hill-Rom (NYSE:HRC) last posted its earnings results on Friday, November 1st. The medical technology company reported $1.69 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.65 by $0.04. The business had revenue of $782.80 million for the quarter, compared to analysts’ expectations of $759.14 million. Hill-Rom had a net margin of 5.24% and a return on equity of 21.67%. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.63 earnings per share. Research analysts anticipate that Hill-Rom Holdings, Inc. will post 5.52 earnings per share for the current year.
A number of research analysts have recently commented on the stock. ValuEngine lowered shares of Hill-Rom from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Barclays upped their price objective on shares of Hill-Rom from $108.00 to $116.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 6th. Morgan Stanley upped their price objective on shares of Hill-Rom from $108.00 to $113.00 and gave the company an “equal weight” rating in a research report on Monday, November 4th. KeyCorp upped their price objective on shares of Hill-Rom from $114.00 to $125.00 and gave the company an “overweight” rating in a research report on Monday, August 5th. Finally, UBS Group upped their price objective on shares of Hill-Rom from $122.00 to $130.00 and gave the company a “buy” rating in a research report on Monday, November 4th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $118.67.
A number of hedge funds and other institutional investors have recently bought and sold shares of HRC. Amundi Pioneer Asset Management Inc. increased its stake in Hill-Rom by 3.4% in the first quarter. Amundi Pioneer Asset Management Inc. now owns 132,190 shares of the medical technology company’s stock valued at $13,993,000 after acquiring an additional 4,312 shares during the period. Private Trust Co. NA increased its stake in Hill-Rom by 3.4% in the second quarter. Private Trust Co. NA now owns 5,345 shares of the medical technology company’s stock valued at $559,000 after acquiring an additional 175 shares during the period. WINTON GROUP Ltd increased its stake in Hill-Rom by 235.7% in the second quarter. WINTON GROUP Ltd now owns 10,762 shares of the medical technology company’s stock valued at $1,126,000 after acquiring an additional 7,556 shares during the period. Cobiz Wealth LLC bought a new stake in Hill-Rom in the second quarter valued at about $5,039,000. Finally, BKD Wealth Advisors LLC bought a new stake in Hill-Rom in the second quarter valued at about $400,000. 82.63% of the stock is currently owned by institutional investors and hedge funds.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Recommended Story: What is a Special Dividend?
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.